Sustainability at Roche

Our approach

For over 120 years Roche has been committed to improving lives. The long-term thinking of our founders has allowed us to stay true to this vision. Our greatest contribution to society is lasting innovation. When acting sustainably, we also aim to provide a rewarding workplace, be a trustworthy partner and engage in the communities we work in and with.

Our impact on society

Innovating for patients

Providing a great workplace

Being a trustworthy partner

Environment and communities

Delivering continuous growth

Innovating for patients

28.9 million

patients treated with Roche medicines

23.4 billion

tests conducted with Roche Diagnostics products

32 Roche medicines

listed on the WHO Model List of Essential Medicines

Providing a great workplace

68% employee engagement rate


31.9% of women

in key leadership positions

40% of women

on the Corporate Executive Committee

Being a trustworthy partner

92 new partnerships

in Pharmaceuticals in 2020

39 new partnerships

in Diagnostics in 2020


of business critical suppliers audited

Environment and communities

19% decrease

in energy consumption since 2015

26% decrease

in general waste since 2015

28.5% decrease

in water consumption since 2015

Delivering continuous growth

+1%* in Group sales


+4%* in core operating profit


21% of sales invested in R&D


*at constant exchange rate

Our reporting

Roche is committed to transparent reporting and we endeavour to drive our economic, social and environmental performance with the same diligence as our financial performance.

External recognition

Our sustainability efforts have been recognised by key ratings such as Dow Jones Sustainability Indices (DJSI) or the Access to Medicine Index (AtMI).

Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI) for the eleventh time. This great result is based on an independent analysis of our economic, social and environmental performance.

Roche ranked 9th in the AtMI in 2021. The Index analyses large research-based healthcare companies on how they make their products more accessible in low- and middle-income countries.